Cantor Fitzgerald assumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and $535 price target Stay Ahead of the Market: ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 2.37% to $477.52 Monday, on what proved to be an all-around dismal trading ...

Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and ...

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Vertex Pharmaceuticals made headlines with a 14% share price jump, despite an overall market dip, thanks to clinical wins and ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...